ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Roflumilast

Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “ARQ-151 cream 0.05%”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.

Drug pageRoflumilast: every studyMany companies study it; this page follows only the 61 they lead. All 118 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 30, 201161 company-led studies, 3 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only340 open or runningphase 4since Mar 30, 2011Jun 9, 2003none ahead
Arcutis Biotherapeuticsits history only181 open or runningphase 3since Dec 23, 2019Dec 29, 2017Apr 27, 2028phase 3 · NCT07916480
Huadong Medicine31 open or runningphase 3since Sep 30, 2024Sep 30, 2024Jun 30, 2027phase 3 · NCT07683806
FLUIDDA nvits history only20 open or runningphase 4since Nov 21, 2011Nov 21, 2011none ahead
Integrative Skin Science and Researchits history only11 open or runningphase 4since Apr 23, 2026Apr 23, 2026Aug 2027phase 4 · NCT07560618
Padagisits history only10 open or runningphase 3since Feb 28, 2023Feb 28, 2023none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 2since Jan 25, 2016Jan 25, 2016none ahead
Takedaits history only10 open or runningphase 1since Mar 4, 2014Mar 4, 2014none ahead

Also a collaborator on its studies: Tanabe Pharma, Fougera Pharmaceuticals and Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Huadong Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2024First study: phase 3 study in Dermatitis, AtopicFirst studyNCT06631170 · 354 enrolled · China
  2. Oct 9, 2024Phase 3 study in Plaque PsoriasisNCT06648772 · 190 enrolled · China
  3. Jun 22, 2026Phase 3 study in Dermatitis, SeborrheicNCT07683806 · 309 planned · China

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Dermatitis, SeborrheicNCT07683806

TargetBeta

“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 5 targets

ProgramCompanyFurthest phaseStudies
ensifentrineruleMerckphase 317

Studies

All 3 Huadong Medicine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07683806Dermatitis, Seborrheic · China3RecruitingJun 30, 2027309
NCT06648772Plaque Psoriasis · China3CompletedOct 13, 2025190
NCT06631170Dermatitis, Atopic · China3CompletedMay 27, 2025354

How it is read

Names in the registry

  • “Roflumilast”, 37 entries
  • “Roflumilast Cream 0.15%”, 5 entries
  • “Roflumilast Cream 0.3%”, 3 entries
  • “ARQ-151 cream 0.05%”, 2 entries
  • “Roflumilast Foam 0.3%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.